

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Strous et al.

Serial No.: To be assigned

Filed: September 12, 2000

For: CONTROLLING AVAILABILITY OR
ACTIVITY OF PROTEINS BY USE OF
PROTEASE INHIBITORS OR RECEPTOR
FRAGMENTS

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 4525US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label
Number: EL700253295US

Date of Deposit with USPS: September 12, 2000

Person making Deposit: Jared Turner



STATEMENT PER 37 C.F.R. § 1.821(f)

Commissioner for Patents
Washington, D.C. 20231

Sir:


I, Kenneth B. Ludwig, registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), are included herewith to comply with the requirements of 37 C.F.R. §§ 1.821-1.825, as requested by the Examiner.

2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the substitute SEQUENCE LISTING.

3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,



Kenneth B. Ludwig
Registration No. 42,814
Attorney for Applicants
TRASK BRITT
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: September 12, 2000

N:\2183\4525\Sequence listing statement.wpd